BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Valeant Pharmaceuticals International (VRX) Trumps Paladin Labs Inc. (CC:PLB) for Afexa Life Sciences Inc. With $78 Million Bid


9/26/2011 8:04:39 AM

Valeant Pharmaceuticals International Inc. (TSX:VRX) said Monday it will sweeten its offer for Afexa Life Sciences Inc. to about $78 million in the escalating battle for the maker of over-the-counter remedy Cold-FX. The Toronto-area company will boost its offer to 85 cents per share, which it said is a 20 per cent premium on its previous offer of 71 cents per share made in August. Valeant is in a bidding war with Montreal-based Paladin Labs Inc. (TSX:PLB), which launched a hostile takeover bid for Afexa (TSX:FXA) in August.

Read at Canadian Business
Read at News Release
Read at CBC
Read at Globe and Mail

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES